Research graph
References from K-Ras-Independent Effects of the Farnesyl Transferase Inhibitor L-744,832 on Cyclin B1/Cdc2 Kinase Activity, G2/M Cell Cycle Progression and Apoptosis in Human Pancreatic Ductal Adenocarcinoma Cell. Local targets link to admitted publications; unresolved targets remain external evidence.
Protein prenylation: molecular mechanisms and functional consequences
10.1146/annurev.bi.65.070196.001325 · 1996 · External reference
The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
10.1146/annurev.pharmtox.37.1.143 · 1997 · External reference
CAAX geranylgeranyl transferase transfers farnesyl as effeciently as geranylgeranyl to RhoB
10.1074/jbc.270.14.7864 · 1995 · External reference
Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
10.1074/jbc.270.11.6221 · 1995 · External reference
cDNA cloning of component A of Rab geranylgeranyltransferase and demonstration of its role as a Rab escort protein
10.1016/0092-8674(93)90639-8 · 1993 · External reference
Ras genes
10.1146/annurev.bi.56.070187.004023 · 1987 · External reference
Proteins regulating ras and its relatives
10.1038/366643a0 · 1993 · External reference
K-ras oncogene activation in adenocarcinoma of the human pancreas
1993 · External reference
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
10.1016/0092-8674(88)90571-5 · 1988 · External reference
Genetic and pharmacologic suppression of oncogenic mutations in RAS genes of yeast and humans
10.1126/science.2569235 · 1989 · External reference
Activation of Raf as a result of recruitment to the plasma membrane
10.1126/science.7811320 · 1994 · External reference
Farnesyltransferase inhibitors: Ras research yields potential cancer therapeutic
10.1016/0092-8674(94)90308-5 · 1994 · External reference
Pre-clinical development of farnesyltransferase inhibitors
10.1023/a:1006018922878 · 1998 · External reference
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
1995 · External reference
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
10.1126/science.8316833 · 1993 · External reference
Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells
10.1126/science.8316834 · 1993 · External reference
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
10.1073/pnas.91.19.9141 · 1994 · External reference
Inhibition of Farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
10.1038/nm0895-792 · 1995 · External reference
Cancer statistics, 1998
10.3322/canjclin.48.1.6 · 1998 · External reference
Resectable pancreatic adenocarcinoma: strategies to improve local tumor control
1998 · External reference
Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines
1995 · External reference
Suppression of pancreatic cancer by the dominant negative ras mutant, N1 16Y
10.1006/jsre.1996.0383 · 1996 · External reference
Enhanced Krev-1 expression inhibits the growth of pancreatic adenocarcinoma cells
10.1097/00006676-199805000-00006 · 1998 · External reference
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions
1994 · External reference
Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinoma
10.1038/ng0994-27 · 1994 · External reference
Negative regulation of Weei expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis
1998 · External reference
p21waf1/cip1 inhibition of cyclin E/Cdk2 activity prevents endoreduplication after miotic spindle disruption
10.1128/mcb.19.1.205 · 1999 · External reference
A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells
10.1074/jbc.273.32.20243 · 1998 · External reference
Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast
10.1101/gad.11.4.504 · 1997 · External reference
Chki is a Weei kinase in the G2 DNA damage checkpoint inhibiting Cdc2 by Y15 phosphorylation
10.1093/emboj/16.3.545 · 1997 · External reference
Premature p34ca°2 activation required for apoptosis
10.1126/science.8108732 · 1994 · External reference
Unscheduled activation of cyclin B1 /Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage
1995 · External reference
Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B
10.1128/mcb.15.2.932 · 1995 · External reference
Requirement of p34Cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1β-converting enzyme-related proteases
1996 · External reference
Resistance of K-ras Bv12 proteins to farnesyltransferase inhibitors in rata cells
10.1073/pnas.93.9.4454 · 1996 · External reference
High affinity for Ftase and alternative prenylation contribute individually to K-ras resistance to FTIs
1999 · External reference
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
1998 · External reference
Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts
10.1002/(sici)1098-2744(199802)21:2<93::aid-mc3>3.0.co;2-p · 1998 · External reference
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation
10.1097/00006676-199409000-00018 · 1994 · External reference
Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment
1997 · External reference
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
10.1128/mcb.18.1.85 · 1998 · External reference
Treatment with farnesyl-protein transferase inhibitor induces regres sion of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
1999 · External reference
GGTI-298 induces GO-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells
1997 · External reference
Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitorinduced apoptosis
1999 · External reference
Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents
10.1073/pnas.95.18.10499 · 1998 · External reference
Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines
1999 · External reference
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
10.1073/pnas.95.4.1369 · 1998 · External reference
X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells
10.1126/science.140.3566.490 · 1963 · External reference
X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells
10.2307/3572025 · 1966 · External reference
Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells
10.2307/3579977 · 1998 · External reference
Taxol sensitizes human astrocytoma cells to radiation
1992 · External reference
K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
10.1074/jbc.272.22.14459 · 1997 · External reference
The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization
1995 · External reference
Non-ras targets of farnesyltransferase inhibitors: focus on Rho
10.1038/sj.onc.1202175 · 1998 · External reference
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
10.1128/mcb.14.6.4193 · 1994 · External reference
Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with Rho activity
10.1128/mcb.15.12.6613 · 1995 · External reference
Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
10.1128/mcb.19.3.1831 · 1999 · External reference
Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesylated inhibitors
1999 · External reference
